GNT Pharma Proves Long-Term Efficacy of "Jedacure" Even in Advanced-Stage Companion Dogs

Post-Marketing Surveillance Results Presented at Seoul Veterinary Clinical Conference

GNT Pharma, a venture company specializing in new drug development, has announced research results showing that Jedacure, the world's first new drug for canine cognitive dysfunction syndrome, demonstrated significant cognitive improvement and safety even with long-term administration in dogs with advanced-stage disease.

On the 20th, at Sejong School in Gwangjin-gu, Seoul, Kim Seongsu, director of VIP Animal Medical Center, presented the post-marketing surveillance results on the topic "Accumulated Real Clinical Experience and New Possibilities of Jedacure" at the 2025 Autumn Seoul Veterinary Clinical Conference Luncheon Symposium. GNT Pharma

According to GNT Pharma on September 22, Kim Seongsu, director of VIP Animal Medical Center, presented the post-marketing surveillance results on the topic "Accumulated Real Clinical Experience and New Possibilities of Jedacure" at the 2025 Autumn Seoul Veterinary Clinical Conference Luncheon Symposium held at the Convention Center of Sejong University in Gwangjin-gu, Seoul, on September 20.

The post-marketing surveillance, a procedure to re-verify the efficacy and safety of approved pharmaceuticals, was conducted at 45 animal hospitals nationwide, including Seoul National University College of Veterinary Medicine, involving approximately 300 companion dogs.

The results showed that in early- and mid-stage patients, just eight weeks of administration reduced the Canine Cognitive Dysfunction Rating (CCDR) score to below 50 (a score of 50 or higher indicates cognitive dysfunction). Notably, even in advanced-stage dogs, long-term administration for 24 weeks or more reduced the score to below 50, confirming a marked improvement in dysfunction. In addition, no hematologic side effects, including changes in liver and kidney values, were observed in dogs even after long-term use.

Director Kim stated, "We observed that elderly dogs suffering from dementia began to recognize their owners again and enjoy daily life together after consistently taking Jedacure," adding, "There was a clear improvement even in advanced-stage dogs with long-term administration, and no organ abnormalities were found, which means owners can use it with peace of mind." He further emphasized, "These results show that Jedacure is not simply a drug that delays symptoms, but a treatment that helps restore the quality of life for companion dogs."

Jedacure, whose efficacy and safety have been proven in dogs with cognitive dysfunction similar to Alzheimer's disease in humans, was approved in 2021 as the first synthetic new drug for veterinary use in Korea and is currently prescribed at over 2,000 animal hospitals nationwide.

Research is also underway to expand the indications of Jedacure to include epilepsy, meningitis, and joint pain, and development of a treatment for cats, which develop cognitive dysfunction through similar pathology to humans, is also in progress.

With the post-marketing surveillance confirming the long-term efficacy and safety of Jedacure, GNT Pharma is expanding its domestic distribution network while accelerating global expansion through overseas regulatory approvals and technology transfer.

Lee Jinhwan, head of GNT Pharma's Animal Business Division, stated, "Jedacure has opened new possibilities for treating dementia in companion animals," adding, "We will continue our research and development so that more companion animals can enjoy a healthy old age."